SynthesisFrontiers in endocrinology2026
Peripheral blood HIF-1α levels in type 2 diabetes mellitus and their association with diabetic complications: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperglycemia is known to exacerbate cellular hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is the functional subunit of the HIF-1 transcription factor and plays a central role in regulating cellular adaptive responses to low oxygen tension. HIF-1α orchestrates these adaptive responses by regulating downstream effectors such as vascular endothelial growth factor (VEGF), which is essential for vascular integrity and metabolic homeostasis. However, while these molecular pathways are well-defined Methods: We conducted a systematic search of major English and Chinese databases (PubMed, Embase, Cochrane Library, Web of Science, Wanfang, CNKI, VIP, and CBM) from inception through September 27, 2025. Cross-sectional studies evaluating peripheral blood protein levels of HIF-1α and VEGF in T2DM patients versus healthy controls were included. Data synthesis was performed using standardized mean differences (SMD) with 95% confidence intervals (CI). Heterogeneity and stability of the results were assessed via subgroup analysis, sensitivity analysis, and Egger's test. Results: Thirty studies were included, comprising 6,400 T2DM patients and 2,994 healthy controls. Meta-analysis revealed significantly elevated peripheral blood levels of both HIF-1α and VEGF in T2DM patients compared to healthy controls. Subgroup analyses confirmed the robustness of these trends across all stratified populations. Sensitivity analyses demonstrated that the findings were robust, and Egger's test indicated no evidence of significant publication bias. Conclusions: The distinct expression profiles of elevated HIF-1α and VEGF underscore their potential involvement in the pathophysiology of T2DM. Our meta-analysis confirms that T2DM is consistently associated with elevated circulating levels of both HIF-1α and VEGF. While these findings underscore the involvement of this molecular axis in T2DM pathophysiology, they do not support their current use as clinical biomarkers or therapeutic targets. The cross-sectional design of the included studies precludes causal inference. Future prospective and mechanistic research is essential to determine their potential utility. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251164744.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.